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The gene coding for the large subunit of herpes simplex virus type 2 ribonucleotide reductase (RR) (ICP10) has a unique
5* terminal domain the product of which has a serine/threonine (Ser/Thr) protein kinase (PK) catalytic domain preceded by
a transmembrane (TM) segment. Because ICP10 localizes on the cell surface and is internalized by the endocytic pathway
like an activated growth factor receptor (Hunter et al., 1995, Virology 210, 345–360), we asked whether it is ligand-inducible
in order to examine whether it has intrinsic transphosphorylating activity. We constructed a chimeric expression vector that
contains the extracellular and TM domains of the epidermal growth factor receptor (EGFR) joined to the intracellular PK
and RR domains of ICP10 (pCH5) and established constitutively expressing cell lines in NIH3T3 2.2 cells that do not express
EGFR. The chimeric protein, designated p210CH5, localized to the surface of these cells as determined by immunofluorescent
staining with MAb EGFR, and it bound 125I-EGF. p210CH5 coprecipitated with protein species p170, p120, p88, p60, p44, p34,
and p25. EGF treatment activated the PK activity of p210CH5, resulting in its autophosphorylation and the phosphorylation
of the p120, p88, and p34 species. Immunoprecipitation/immunoblotting with anti-ras-GAP antibody and phosphoamino acid
analysis indicated that p120 is ras-GAP and it is phosphorylated on Ser/Thr residues. The identities of the phosphorylated
p88 and p34 are still unknown. The data indicate that when fused to a ligand-regulated extracellular domain (EGFR), the
ICP10 PK auto- and transphosphorylating activities are ligand-inducible. These findings support the interpretation that the
ICP10 PK activity is intrinsic and indicate that ras-GAP is one of its phosphorylation substrates. q 1996 Academic Press, Inc.
INTRODUCTION HSV-1 and ICP10 for HSV-2. The small subunit (RR2) is
a 38-kDa protein encoded by a 1.2-kb mRNA overlapping
Ribonucleotide reductase (RR) is an essential enzyme
the 3* end of the 5.0-kb mRNA that encodes RR1 (Ander-
for the conversion of ribonucleotides to the correspond-
son et al., 1981; McLauchlan and Clements, 1983).
ing deoxyribonucleotides in eukaryotic and prokaryotic
The HSV RR1 genes differ from their counterparts in
cells, and its activity may represent the rate-limiting step
eukaryotic and prokaryotic cells and in other viruses in
in DNA synthesis and concomitant cell growth (The-
that they possess a unique one-third 5*-terminal domain
lander and Reichard, 1979). Several herpesviruses, in-
(Nikas et al., 1986; Swain and Galloway, 1986). The ICP10
cluding HSV-1, HSV-2, EBV, VZV, pseudorabies virus, and unique domain (ICP10 PK oncogene) causes neoplastic
equine herpesvirus types 1 and 3, induce a novel distinct transformation of immortalized cells (Jariwalla et al.,
RR activity (Cohen et al., 1977; Henry et al., 1978; Lanki- 1980; Hayashi et al., 1985; Iwasaka et al., 1985; Smith et
nen et al., 1982; Averett et al., 1983; Dutia, 1983; Davison al., 1992, 1994). Its protein product has conserved protein
et al., 1986) that may be required for virus growth in kinase (PK) catalytic motifs characteristic of serine/threo-
nondividing cells (Goldstein and Weller, 1988a,b; Preston nine (Ser/Thr)-specific kinases which are preceded by
et al., 1988; Jacobson et al., 1989). The HSV RR differs features of a transmembrane (TM) helical segment
from the cellular enzyme in that it is insensitive to dTTP (Smith et al., 1994; Chung et al., 1989, 1990; Luo and
and dATP inhibition and does not have an absolute Mg2/ Aurelian, 1992). Two proline-rich regions consistent with
requirement (Langelier and Buttin, 1981). However, like core SH3-binding motifs that might be involved in pro-
the mammalian and bacterial enzymes, the HSV RR activ- tein–protein interactions (Pawson, 1995) were also iden-
ity is formed by the association of two distinct subunits, tified (Smith et al., 1994).
the coding regions of which do not overlap. The large A wealth of evidence indicates that the PK activity is
subunit (RR1) is a 140-kDa protein, designated ICP6 for an intrinsic property of ICP10. Thus: (i) expression of the
ICP10 PK oncogene (amino acids 1–411) in eukaryotic
or in bacterial expression systems permits the synthesis1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (410) 706-2513. of an enzymatically active protein (Chung et al., 1989;
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Luo et al., 1991), (ii) ICP10 binds the 14C-labeled ATP
analogue p-fluorosulfonylbenzoyl 5*-adenosine (FSBA)
and binding is specifically competed by another ATP ana-
logue, AMP-PNP (Luo and Aurelian, 1992), (iii) ICP10 ki-
nase activity is retained after electrophoresis on denatur-
FIG. 1. Schematic representation of ICP10 and the epidermal growthing gels and renaturation on a nitrocellulose membrane
factor (EGFR)/ICP10 hybrid protein p210CH5. ICP10 consists of an extra-(Luo and Aurelian, 1992), (iv) an ICP10 mutant deleted in
cellular domain (at residues 1–85), transmembrane segment (TM) (resi-the conserved PK catalytic motifs is PK negative and
dues 86–106), protein kinase (PK) catalytic domain (residues 107–
does not bind FSBA (Luo and Aurelian, 1992), (v) PK 411), and ribonucleotide reductase (RR) domain (residues 411–1144).
activity is also lost by deletion of the TM segment al- p210CH5, the product of the pCH5 chimera, contains the extracellular
and TM domains from EGFR (amino acids 1–687) and the PK and RRthough the mutant protein retains all known target sites
domains from ICP10 (amino acids 107–1144).for cellular kinases (Luo and Aurelian, 1992; Smith et al.,
1994; Hunter et al., 1995a), and (vi) mutation of Lys176
significantly decreases (Luo and Aurelian, 1992), almost construct (pCH5) in which both the extracellular domain
abrogates (Peng et al., 1996), PK activity and FSBA bind- and the TM segment of ICP10 were replaced by the
ing both in eukaryotic and in prokaryotic cells. It is un- corresponding domains of the epidermal growth factor
likely that the ATP-binding Lys is located at the exact receptor (EGFR). The data indicate that the ICP10 PK
same site in ICP10 and in putative contaminating eukary- catalytic domain can function as an inducible kinase,
otic and prokaryotic kinases. Recent studies of the HSV-1 supporting the conclusion that its PK activity is intrinsic.
RR1 (ICP6) also concluded that the PK activity is intrinsic
(Conner et al., 1992; Cooper et al., 1995). MATERIALS AND METHODS
ICP10 is associated with the plasma membrane with
Plasmidsa polarity that identifies the TM as a membrane-spanning
domain (Strnad and Aurelian, 1978; Smith et al., 1994; pCH5 consists of the EGFR extracellular and TM do-
Chung et al., 1989; Luo and Aurelian, 1992; Hunter et al., mains and the ICP10 intracellular PK domain (Fig. 1). To
1995a,b). Immunogold electron microscopy indicates that construct pCH5, the EGFR cDNA (obtained from A. Ull-
ICP10 is localized on the cell surface and it is internalized rich) was digested with HindIII and EcoRI. The resulting
by the endocytic pathway, and deletion of the TM seg- 2.3-kb fragment that encodes the EGFR extracellular and
ment eliminates cell surface localization (Smith et al., TM domains was ligated into the TM-deleted ICP10 mu-
1994; Hunter et al., 1995a,b). Consistent with the interpre- tant pJHL15 that contains an EcoRI linker (Luo and Aure-
tation that ICP10 kinase activity is intrinsic, the activity is lian, 1992). Prior to ligation pJHL15 had been digested
required in order to induce activation of the ras signaling with HindIII/EcoRI to remove a 261-bp fragment encoding
pathway and transformation (Smith et al., 1992, 1994; ICP10 residues 1–87. The resulting chimera, designated
Hunter et al., 1995a). pCH1, was digested with HindIII/ScaI, and a 3.4-kb frag-
Although ICP10 fulfills the same stringent criteria for ment that encompasses the EGFR extracellular and TM
intrinsic kinase activity that were used for established domains and ICP10 PK amino acids 106–351 was ligated
cellular PKs (Gibbs and Zoller, 1991; Taylor et al., 1992), into the HindIII/ScaI-collapsed pJW17N that contains the
recent conflicting results relative to the RR1 transphos- constitutive simian cytomegalovirus IE94 promoter and a
phorylating potential in HSV-infected cells (Ali, 1995) SV2neo cassette (Luo and Aurelian, 1992). pCH5 contains
have again raised the question of the intrinsic nature of DNA sequences encoding EGFR amino acids 1–687 and
this activity. Since biochemical criteria for intrinsic activ- ICP10 amino acids 107–1144.
ity were already studied, and in order to focus on trans-
phophorylating potential, we constructed a chimeric mol- Cells
ecule in which the extracellular domain of ICP10 is re-
NIH3T3 mouse clone 2.2 fibroblasts which do not ex-placed by the ligand-binding extracellular region of a
press detectable levels of endogenous EGFR, erbB2,growth factor receptor whose ligand is known and used it
erbB3, or erbB4 (Levaslaiho et al., 1989; Lee et al., 1989;to examine whether ICP10 PK activity is ligand-inducible.
Margolis et al., 1990; Osherov et al., 1993; Kraus et al.,This approach is based on previous studies of chimeric
1993) were obtained from I. Lax (Rorer Biotech, Inc.) andmolecules in which the intracellular signals induced
maintained in Dulbecco’s modified minimal essential me-upon stimulation with the appropriate ligand were shown
dium (DMEM) with 10% fetal bovine serum (FBS).to be determined by the cytoplasmic (PK catalytic do-
main) rather than the extracellular portion of the molecule
Antibodies
(Ellis et al., 1987; Lee et al., 1989; Lehvaslaiho et al.,
1989; Riedel et al., 1987, 1989, 1994; Di Fiore et al., 1990; Polyclonal antibody anti-LA-1 to a peptide located up-
stream of the ICP10 TM (amino acids 13–26) and mono-Seedorf et al., 1991; Lhotak and Pawson, 1993). Here
we describe the results of our studies with a chimeric clonal antibodies (MAbs) H3 and G8 that respectively
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recognize determinants located at ICP10 amino acids sucrose, 0.04% bromthymol blue]. Proteins were resolved
by SDS–PAGE on polyacrylamide gels and visualized414–1144 and 1–283 were described (Aurelian et al.,
1989; Chung et al., 1991). MAb EGFR 528, which recog- by autoradiography. In some experiments, the resolved
proteins were transferred to nitrocellulose membranesnizes the EGFR extracellular domain, was obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-ras-GAP and immunoblotted with specific antibodies. Detection
was with the ECL detection system. For immunoprecipi-antibody (06-153) was purchased from Upstate Biotech-
nology, Inc. (Lake Placid, NY). tation/immunoblotting experiments with anti-ras-GAP an-
tibody, cells were resuspended in a buffer consisting of
Metabolic labeling 50 mM HEPES, pH 7.5, 0.15 mM NaCl, 1% Triton X-100,
10% glycerol, 100 mM sodium fluoride, 1 mM sodiumLabeling and preparation of whole cell extracts was
vanadate, 10 mM sodium pyrophosphate, 1 mM PMSF,as described (Smith et al., 1994; Luo and Aurelian, 1992;
and 100 kallikrein units/ml aprotinin. After 30 min of incu-Hunter et al., 1995a). Cells were labeled with [35S]-
bation on ice, the extracts were clarified by centrifugationmethionine (100 mCi/ml; sp act 1120 Ci/mmol; Dupont
at 16,000 g for 30 min. Quantitative analyses were doneNEN Research Products, Boston, MA) in methionine-free
by densitometric scanning of samples equilibrated forDMEM with 10% FBS (18 hr, 377) and resuspended in
protein content using a Molecular Dynamics Imageice-cold RIPA buffer [150 mM NaCl, 20 mM Tris–HCl (pH
Quant computing densitometer Model 300B (Smith et al.,7.4), 0.1% sodium dodecyl sulfate (SDS), 1% Nonidet P-
1994).40 (NP-40), 1% sodium deoxycholate, 1 mM phenylmeth-
ylsulfonyl fluoride (PMSF) (Sigma Chemical Co., St. Louis,
EGF bindingMO), 100 kallikrein units/ml aprotinin (Sigma)]. In some
experiments, cells were serum starved by growth (24 hr) EGF binding was measured as described by Lhotak
in DMEM with 0.5% FBS and labeled with [32P]- and Pawson (1993). Cells were plated in 12-well plates
orthophosphate (500 mCi/ml; NEN) in phosphate-free at a density of 1 1 105 cells/well. The next day the plates
EMEM with 0.5% FBS (2 hr, 377). They were stimulated were cooled on ice, washed twice with ice-cold washing
(15 min, 377) with 1 mg/ml epidermal growth factor (EGF) buffer (PBS with 1 mg/ml BSA), and incubated (2 hr) on
or mock-treated with phosphate-buffered saline, pH 7.3 ice in washing buffer containing 1 ng/ml 125I-EGF (Amer-
(PBS). Labeled cells were resuspended in a buffer con- sham) in the presence or absence of 100-fold excess
sisting of 50 mM HEPES (pH 7.5), 0.15 M NaCl, 1% NP- cold EGF (Upstate Biotechnology). Cells were washed
40, 5 mM EDTA, 10 mM sodium pyrophosphate, 1 mM five times with ice-cold washing buffer, lysed in 0.2%
sodium vanadate, 100 mM sodium fluoride, 1 mM PMSF, SDS–0.2 N NaOH and counted in a scintillation gamma
and 100 kallikrein units/ml aprotinin, incubated on ice for counter (Beckman). Cell protein was measured from du-
15 min, and disrupted by sonication for 1 min at maximum plicate wells treated as above but without the addition
setting in an Ultrasonics Model 220F sonicator. The ex- of radioactive isotope. Protein was assayed using the
tracts were clarified by centrifugation (30 min) at 16,000 g BCA protein assay kit (Pierce Chemicals, Rockford, IL)
and the supernatants were used in immunoprecipitation. according to the manufacturer’s instructions.
Immunofluorescent staining Phosphoamino acid analysis
Immunofluorescent staining of unfixed (membrane) Extracts of CH5 cells were assayed for in vitro PK
cells was done as described (Wymer et al., 1989; Smith activity by immunocomplex assay with MAb H3, and the
et al., 1994). Flow cytometric analysis was performed on 32P-labeled p210CH5 and p120 were identified. Gel sec-
a Beckton–Dickinson FACScan cytometer equipped with tions corresponding to p210CH5 and p120 were excised,
a 150-mW laser. The cells were excited with 488 nm and homogenized in 2 ml of 50 mM ammonium bicarbonate
fluorescence was collected through a 530/30 filter. Ten with 0.1% SDS–1 mM EDTA–10 mg of bovine serum albu-
thousand events were stored in list mode and later ana- min per milliliter (16 hr, 377). The eluted proteins were
lyzed using the Consort 40 analysis software from Beck- cleared of gel debris by filtration through a 0.22-mm cellu-
ton–Dickinson. lose acetate filter (Spin-X, Co-Star) and were trichloro-
acetic acid (20% final concentration) precipitated. Follow-
Immunoprecipitation and immunoblotting
ing centrifugation (15 min, 16,000 g, 47), the precipitates
were washed with cold absolute ethanol and cold etha-For immunoprecipitation, cell extracts were incubated
(1 hr, 47) with 10–15 ml of antibody and (30 min, 47) with nol–diethyl ether (50% v/v), suspended in 100 ml of boil-
ing 6 N HCl, and incubated 1 hr at 1107. The hydrolysates100 ml of protein A–Sepharose CL4B beads (50% v/v,
Sigma). Beads were washed three times with ice-cold were lyophilized and resolubilized in 10 ml of a marker
mixture containing 1 mg each of phosphoserine, phos-RIPA buffer and bound proteins were eluted by boiling
(5 min) in 50 ml of denaturing solution [150 mM Tris – phothreonine, and 04-phosphotyrosine per milliliter
(Sigma). Phosphoamino acids were separated by two-HCl (pH 7.0), 5.7% SDS, 14% b-mercaptoethanol, 17%
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dimensional paper electrophoresis at pH 2.3 for 2.4 hr
at 400 V in 1 M acetic acid followed by pH 5.0 for 2.5 hr
at 400 V in 0.1 M pyridine acetic acid. The positions of
the markers were ascertained by staining with ninhydrin
spray reagent (Sigma) and the 32P-labeled amino acids
were visualized by autoradiography (Chung et al., 1989).
RESULTS
Stable transfection and expression of EGFR/ICP10
hybrid protein
We have previously shown that: (i) the ICP10 TM seg-
ment is a membrane-spanning domain and (ii) ICP10 PK
activity is required to cause activation of the ras signaling
pathway (Smith et al., 1994; Hunter et al., 1995a). Based
on these observations, and in order to further examine
whether ICP10 has intrinsic kinase activity, we con-
structed an expression vector for EGFR/ICP10 chimera
(pCH5) which contains DNA sequences that encode a
FIG. 2. Expression and phosphorylation of p210CH5. (A) Extracts fromprotein (p210CH5) in which the EGFR extracellular and TM
[35S]methionine-labeled CH5a cells (lanes 3 and 4) were immunoprecip-
domains (EGFR amino acids 1–687) are joined to the itated with Mab H3 (lane 4) or normal rabbit serum (NRS) (lane 3).
ICP10 intracellular domains (ICP10 amino acids 107– Extracts from serum-starved CH5a (lanes 5–8) or NIH3T3 2.2 cells
(lanes 1 and 2) labeled with [32P]orthophosphate and treated with PBS1144). The vector also contains a SV2neo cassette to
(lanes 1, 5, and 7) or with 1 mg/ml EGF (lanes 2, 6, and 8) for 15 minfacilitate establishment of stably transfected cell lines.
were immunoprecipitated with MAb H3 (lanes 1, 2, 5, and 6) or MAbpCH5 retains ICP10 intracellular sequences that contain
G8 (lanes 7 and 8). Precipitated proteins were resolved by 9.5% SDS–
all the known targets for cellular kinases. Therefore, if PAGE. (B) Extracts from [35S]methionine-labeled NIH3T3 2.2 (lane 1)
the ICP10 PK activity is due to a contaminating, albeit or CH5a (lane 2) cells were immunoprecipitated with MAb to EGFR.
Precipitated proteins were resolved by 9.5% SDS–PAGE. Similar resultsinvisible, cellular PK, ICP10 should be constitutively
were obtained for all independently established CH5 cell lines. Molecu-phosphorylated in cells that express pCH5. Alternatively,
lar weight markers are listed in the margins.if the ICP10 PK activity is intrinsic, phosphorylation
should be ligand-stimulated.
NIH3T3 2.2 cells that do not express detectable levels tive molecular weights of 170, 120, 88, 60, 44, 34, and 25
kDa coprecipitated with p210CH5 (Fig. 2A, lane 4). Theof EGFR, erbB2, erbB3, or erbB4 (Levaslaiho et al., 1989;
Lee et al., 1989; Margolis et al., 1990; Osherov et al., coprecipitating proteins are not proteolytic breakdown
products of the 210-kDa chimera protein nor are they1993; Kraus et al., 1993) were transfected with pCH5
followed by G418 selection (400 mg) as described (Luo unrelated proteins that share an epitope with p210CH5,
since similar results were obtained with MAb G8 (Fig. 2A,and Aurelian, 1992; Smith et al., 1994). Individual colonies
were independently isolated and stable cell lines were lanes 7 and 8) that recognizes a different ICP10 epitope
(Chung et al., 1991) or MAb EGFR (Fig. 2B, lane 2) thatestablished. Three cell lines (CH5a, CH5b, and CH5f)
were chosen for further passage and analysis. To deter- is unrelated to ICP10. The levels of the coprecipitating
p60 and p34 were significantly lower in the MAb EGFRmine whether the hybrid proteins are expressed in these
cell lines, total extracts of cells labeled with [35S]- than the MAb H3 immunoprecipitates. This may reflect
a different stoichiometric interaction than that seen formethionine (5 1 106 cells; 1200 mg protein) were precipi-
tated with MAb H3 (recognizes a determinant in the the other coprecipitating proteins which appear to be
equally distributed in the MAb H3 and MAb EGFR immu-ICP10 RR domain) or with MAb EGFR (recognizes a deter-
minant in the EGFR extracellular domain) and separated noprecipitates. Proteins were not precipitated from
NIH3T3 2.2 cells (Fig. 2A, lane 2; Fig. 2B, lane 1) nor byby SDS–PAGE as previously described (Luo and Aure-
lian, 1992; Smith et al., 1992, 1994). normal rabbit serum (NRS) (Fig. 2A, lane 3). Proteins p170
and p25 are consistent with the complex of the guanineAs shown in Fig. 2 for one representative cell line
(CH5a), a protein (p210CH5) with the expected molecular exchange factor hsos and the adaptor protein Grb2 (Char-
din et al., 1993; Li et al., 1993), and immunoblotting ofweight for the chimera protein was precipitated by MAb
H3 from [35S]methionine-labeled CH5 cells (Fig. 2A, lane the MAb H3 precipitates with antibody to hsos or Grb2
confirmed their identity (C. C. Smith et al., in preparation).4). Its expression levels were similar in all three indepen-
dently established cell lines, as determined by densito- These proteins bind ICP10 in stably transfected human
cells (Smith et al., 1994) and or NIH3T3 cells (C. C. Smithmetric scanning of the immunoprecipitates (densitomet-
ric integration units  3348 { 150). Proteins with respec- et al., in preparation).
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laiho et al., 1989; Lhotak and Pawson, 1993; Riedel et
al., 1987; Lax et al., 1989).
ras-GAP binds p210CH5
ras-GAP is a 120-kDa protein that functions as a nega-
tive regulator of ras (Satoh et al., 1990a,b; Molloy et al.,
1992). It stimulates the otherwise weak intrinsic GTPase
activity of ras, thereby promoting its return to an inactive,
GDP-bound state (Trahey and McCormick, 1987; McCor-
mick, 1989). Since ras-GAP binds to ICP10 in stably
transfected (constitutively expressing) human cells
(Smith et al., 1994), and a p120 species coprecipitates
with p210CH5, these studies sought to determine whether:
(i) ras-GAP binds p210CH5 and (ii) binding is dependent
on EGF treatment. To address these questions, CH5 cells
were serum starved and exposed to EGF (or PBS control)
for 15 min as described above. Extracts obtained at this
time were immunoprecipitated with MAb H3 or NRS con-
trol and the proteins, resolved by SDS–PAGE and trans-
ferred to nitrocellulose membranes, were immunoblotted
FIG. 3. FACS analysis of CH5b (arrow) and NIH3T3 2.2 cells stained with anti-ras-GAP antibody. As shown in Fig. 5 for CH5f
in membrane immunofluorescence with Mab EGFR. Scans of CH5b cells, ras-GAP was observed in both the EGF-treated
and NIH3T3 2.2 cells stained with NRS or anti-LA-1 antibody overlap
(Fig. 5, lane 4) and untreated (Fig. 5, lane 3) cells. It wasthe NIH3T3 2.2 cells stained with MAb EGFR. Similar results were
not seen in the NRS immunoprecipitates (Fig. 5, lanes 1obtained for all independently established CH5 cell lines.
and 2). Similar results were obtained for all three CH5
lines and for precipitates obtained with MAbs G8 or
p210CH5 localizes on the cell surface EGFR. We interpret these findings to indicate that the
coprecipitating p120 is ras-GAP and its binding toWe used membrane immunofluorescent staining with
p210CH5 is ligand-independent.the EGFR MAb in order to determine whether p210CH5
localizes to the cell surface. As shown in Fig. 3, 97–99%
EGF activates the PK activity of p210CH5
of the CH5 cells stained with the EGFR antibody. NIH3T3
2.2 cells did not stain with MAb EGFR and preimmune Ligand binding to the extracellular domain of EGFR
serum was negative. triggers autophosphorylation and transphosphorylation
of several intracellular substrates on tyrosine residues
p210CH5 binds EGF
To determine whether the hybrid protein retains EGF
binding potential, we examined the ability of CH5 cells
to bind 125I-labeled EGF. The protocol, similar to that pre-
viously described for EGFR chimeric proteins (Lee et al.,
1989), involved cell exposure to 125I-EGF in the presence
or absence of 10- to 100-fold excess cold EGF. CH5 cells
bound the 125I-labeled EGF (275 cpm/mg protein) and the
radioactivity was competed by cold EGF. This is shown
in Fig. 4 for a 100-fold excess of EGF. 125I-EGF did not
bind to NIH3T3 2.2 cells, consistent with previous reports
(Margolis et al., 1990). We estimate that CH5 cells ex-
press 1 1 105 specific EGF-binding sites/cell. This
compares to 2 1 106 receptors/cell in A431 cells studied
in parallel (data not shown). These findings indicate that
(i) CH5 cells express specific EGF-binding sites on the
FIG. 4. Binding of 125I-EGF to the p210CH5 chimera. CH5f and NIH3T3cell surface which are not present on NIH3T3 2.2 cells
2.2 cells (1 1 105 cells/well) were incubated on ice with 1 ng/ml 125I-and (ii) the levels of EGF-binding receptors on CH5 cells
EGF in the absence (‰) or presence (h) of 100-fold excess nonradioac-
are 20-fold lower than those in A431 cells (Haigler et tive EGF. The results represent mean values from three independent
al., 1978; Lehvaslaiho et al., 1989) but within the range experiments. Similar results were obtained for all independently estab-
lished CH5 cell lines.previously reported for EGFR hybrid proteins (Lehvas-
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body confirmed that the phosphorylated p120 is ras-GAP
(Fig. 6A, lane 1). ras-GAP was also seen in immunoblot-
ting (with anti-ras-GAP antibody) of the precipitates from
untreated CH5 cells (Fig. 6A, lane 2), but it was not seen
in precipitates from NIH3T3 cells (Fig. 6A, lane 3). Phos-
phoamino acid analysis of the phosphorylated p210CH5
and ras-GAP coprecipitated with p210CH5 from EGF-
treated CH5 cells indicated that both are phosphorylated
on serine/threonine (Figs. 6B and 6C), consistent with
the specificity of ICP10 PK. These findings indicate that
EGF stimulation induces the kinase activity of p210CH5,
and ras-GAP is a phosphorylation substrate of the EGF-
activated p210CH5. The identity of the other proteins phos-
phorylated by EGF treatment of CH5 cells is still unclear.
FIG. 5. ras-GAP binds the p210CH5 chimera protein. Extracts from DISCUSSION
serum-starved (24 hr, 0.5% FBS) CH5f cells treated with PBS (lanes 1
and 3) or with 1 mg/ml EGF (lanes 2 and 4) were immunoprecipitated The HSV-2 RR1 gene differs from its counterparts in
with MAb G8 (lanes 3 and 4) or NRS (lanes 1 and 2) and electrotrans- eukaryotic and prokaryotic cells and in other viruses in
ferred to nitrocellulose membranes. They were immunoblotted with that it possesses a unique 5*-terminal domain that has
anti-ras-GAP antibody. Similar results were seen for all three CH5 lines
transforming activity (ICP10 PK oncogene) and encodesand for immunoprecipitates obtained with MAb H3 or MAb EGFR. Mo-
a protein that has conserved PK catalytic motifs precededlecular weight markers are shown in the right margin.
by a TM segment and an extracellular domain (Smith et
al., 1994; Chung et al., 1989, 1990; Hunter et al., 1995a).(van der Geer et al., 1994). Since the hybrid p210CH5 pro-
tein contains the ICP10 PK catalytic domain which is Ser/
Thr specific, the question arises whether its PK activity
is triggered by EGF binding. To address this question,
CH5 cells were serum starved by 24 hr of incubation in
medium containing 0.5% FBS and labeled (2 hr, 377) with
[32P]orthophosphate before stimulation (15 min) with 1
mg/ml EGF or PBS. NIH3T3 2.2 cells served as control.
Cell extracts obtained at this time were precipitated with
MAb H3 and analyzed by SDS–PAGE. Autophosphory-
lated p210CH5 was precipitated from EGF-treated (Fig. 2A,
lane 6) but not untreated (Fig. 2A, lane 5) CH5 cells. Other
phosphorylated proteins precipitated from EGF-treated,
but not untreated, CH5 cells were p120 (ras-GAP), p88,
p60, and p34 (Fig. 2A, lane 6). A phosphorylated 60-kDa
protein was also precipitated from PBS-treated CH5 cells
(Fig. 2A, lane 5) but its levels were significantly (three-
to fivefold) higher in the precipitates from the EGF-treated
cells (Fig. 2A, lane 6). Although p170, p25, and p44 pro-
teins coprecipitated with p210CH5 from [35S]methionine-
labeled cells (Fig. 2A, lane 4) they were not phosphory-
lated (Fig. 2A, lane 6), suggesting that ICP10-mediated
phosphorylation is specific and only some of the proteins
which bind p210CH5 are phosphorylated by its ligand-
induced activation. Similar results were obtained with
MAb G8 (Fig. 2A, lanes 7 and 8), indicating that this was
not an artifact due to the use of a specific MAb in the
immunocomplex PK assay. Phosphorylated proteins
FIG. 6. (A) Immunoblotting of the MAb H3 PK immunocomplex assayswere not seen in the precipitates from the EGF-treated
of EGF-treated (lane 1) or untreated (lane 2) CH5a cells or of NIH3T3NIH3T3 2.2 cells (Fig. 2A, lane 2) and NRS was negative
2.2 cells (lane 3) with anti-ras-GAP antibody. (B) Phosphoamino acid
(data not shown). analysis of the phosphorylated ras-GAP from EGF-treated CH5f cells.
Immunoblotting of the MAb H3 precipitates from EGF- (C) Phosphoamino acid analysis of the phosphorylated p210CH5 from
EGF-treated CH5f cells.treated (Fig. 2A, lane 6) CH5 cells with anti-ras-GAP anti-
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The oncoprotein is located on the cell surface and is most notably CKII (Langelier, personal communication).
In addition to the above-summarized evidence which ar-internalized by the endocytic pathway. It induces activa-
tion of the ras signaling pathway and causes increased gues against this interpretation, ICP10 PK is Mn2/-depen-
dent for optimal activity (Peng et al., 1996) while CKII iscell proliferation and anchorage-independent growth.
Membrane anchorage and PK activity are required for Mg2/-dependent for optimal PK activity (Gatica et al.,
1993) and ICP10 PK activity does not require monovalentsignaling and anchorage-independent growth (Smith et
al., 1994; Hunter et al., 1995a). Comparison of the ICP10 cations and is not inhibited by zinc sulfate (Peng et al.,
1996), unlike CKII (Gatica et al., 1993). However, sincePK oncoprotein to the superfamily of Ser/Thr GFRs in the
current versions of SwissProt (v27.0) and Genbank most of these studies did not specifically address the
question of transphosphorylation, we took advantage of(v80.0) databases and analysis by the GCG/Wisconsin
(v8.0) DISTANCES program indicate that the oncoprotein the observation that ICP10 has properties of a GFR to
construct a chimera protein in which the function/speci-is a member of a novel subfamily of Ser/Thr GFR kinases
(Hunter et al., 1995b). One outstanding difference be- ficity of ICP10 kinase can be examined under conditions
of controlled ligand-induced activation.tween the ICP10 PK oncoprotein and known members
of the superfamily is the presence of two proline-rich Hybrid receptors were previously used to elucidate
the biological and biochemical activities of GFR ki-regions that closely resemble core SH3-binding motifs,
at positions 150 and 396 within the PK catalytic domain nases, the ligand of which is unknown. Chimeras were
constructed between different tyrosine kinases includ-(Smith et al., 1994). The exact function of these motifs is
still unknown. However, a bacterially expressed onco- ing EGFR/fms, EGFR/v-src (Riedel, 1994), EGFR/neu
(Lehvaslaiho et al., 1989), and EGFR-ret (Santoro et al.,protein mutant that retains only the proline-rich SH3-bind-
ing motif at position 150 binds Grb2 in vitro after it is 1994). Hybrids constructed from receptor molecules
were functional with respect to protein expression, cellpurified to homogeneity (M. Santana-Verano, personal
communication), suggesting that these motifs may be surface localization, and ligand binding (Lehvaslaiho et
al., 1989; Lhotak and Pawson, 1993; Riedel, 1994; San-involved in the binding of signaling proteins.
A wealth of evidence indicates that the ICP10 PK activ- toro et al., 1994). They also displayed ligand-responsive
kinase activity and, at least in some cases, mitogenicity is intrinsic. Thus: (i) expression of the ICP10 PK onco-
gene (amino acids 1 – 411) in eukaryotic or in bacterial responses (Santoro et al., 1994). The contribution of
the TM origin was addressed in a study of EGFR-elkexpression systems permits the synthesis of an enzymat-
ically active protein (Luo et al., 1991), (ii) ICP10 binds the receptors and found to be insignificant. However, unlike
the wild type EGFR expressed in the same cells, the14C-labeled ATP analogue FSBA and binding is inhibited
by another ATP analogue, AMP-PNP (Luo and Aurelian, EGFR-elk chimeras did not induce neoplastic changes
or enhance cell growth (Lhotak and Pawson, 1993). A1992), (iii) kinase activity is retained after ICP10 electro-
phoresis on denaturing gels and renaturation on a nitro- hybrid consisting of the extracellular and TM domains
of EGFR and the intracellular domain of v-src (which iscellulose membrane (Luo and Aurelian, 1992), (iv) an
ICP10 mutant deleted in the PK catalytic domain is PK not a plasma membrane-spanning protein) displayed a
ligand-unresponsive v-src tyrosine kinase and did notnegative and does not bind FSBA (Luo and Aurelian,
1992), (v) kinase activity is not due to contaminating cellu- evidence cell-transforming activity or increased DNA
synthesis (Riedel, 1994). Our construction strategy waslar kinases since an ICP10 mutant deleted in the TM
segment retains all known target sites for cellular ki- based on these findings. The EGFR ligand-binding ex-
tracellular domain was selected for these studies be-nases but is PK negative (Luo and Aurelian, 1992; Smith
et al., 1994; Hunter et al., 1995a) — the deleted TM is not cause it had been previously used to construct chimeric
proteins in which intracellular signals induced by EGFthe binding site for cellular kinases since it is a trans-
membrane-spanning segment (Hunter et al., 1995a,b), stimulation were shown to be mediated by the PK cata-
lytic domains rather than the extracellular EGFR do-and (vi) mutation of Lys176 significantly decreases (Luo
and Aurelian, 1992), almost abrogates (Peng et al., 1996), mains or the formation of heterodimers with erbB2,
erbB3, or erbB4 (Ellis et al., 1987; Lee et al., 1989; Leh-the PK activity and FSBA binding of ICP10 expressed in
eukaryotic cells and bacteria and it is unlikely that the vaslaiho et al., 1989; Riedel et al., 1989; Di Fiore et al.,
1990; Seedorf et al., 1991; Lhotak and Pawson, 1993;putative eukaryotic and bacterial contaminating kinases
have the same ATP binding site as that mutated in ICP10. Osherov et al., 1993; Kraus et al., 1993). To control for
the potential contribution of conformational changes re-It is noteworthy that similar types of evidence have
been used to establish that cellular kinases have intrinsic sulting from its deletion, the ICP10 RR domain was re-
tained. Stably transfected lines were established inenzymatic activity (Gibbs and Zoller, 1991; Taylor et al.,
1992). Notwithstanding, recent conflicting results relative NIH3T3 2.2 cells because they do not contain endoge-
nous EGFR, erbB2, erbB3, or erbB4 (Levaslaiho et al.,to the transphosphorylating potential of RR1 PK (Ali, 1995)
have raised the possibility that the ICP10 PK activity is 1989; Lee et al., 1989; Margolis et al., 1990; Kraus et
al., 1993; Osherov et al., 1993) and therefore the EGFdue to a contaminating, albeit invisible, cellular kinase,
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signal must be mediated by the EGFR/ICP10 hybrid pro- is also phosphorylated by p210CH5. The identities of these
phosphorylated proteins are still unclear. Other proteinstein (p210CH5).
We found that p210CH5, which retains the ligand-regu- which coprecipitate with p210CH5 from [35S]methionine-
labeled cells (p170, p25, and p44) were not phosphory-lated extracellular domain and TM segment of EGFR, is
expressed in stably transfected cell lines, localizes to lated after EGF treatment, suggesting that the transphos-
phorylating activity of p210CH5 is specific. The levels ofthe cell surface, and binds EGF. The proportion of cells
expressing high levels of p210CH5 on the cell surface, the EGF that induced phosphorylation (100–1000 ng/ml) are
within the range previously described for EGFR chimeraestimated number of EGF-binding sites, and the levels
of bound 125I-EGF were within the range previously de- proteins (Lhotak and Pawson, 1993; Santoro et al., 1994).
The hybrid receptor p210CH5 replicates the behavior ofscribed for EGFR chimera proteins (Lehvaslaiho et al.,
1989; Lhotak and Pawson, 1993; Riedel et al., 1987; Lax the wild type ICP10 in that it binds ras-GAP as well as
other cellular proteins potentially involved in signaling,et al., 1989). Similar results were obtained for all three
independently established CH5 lines, suggesting that and when its PK activity is stimulated by EGF treatment,
it phosphorylates a number of proteins including ras-this is not an artifact, unique to one cell line. Immunopre-
cipitation/immunoblotting assays similar to those pre- GAP. However, phosphorylation is not indiscriminate, as
some of the proteins that bind p210CH5 are not phosphor-viously used to determine GFR binding to signaling pro-
teins (Lowenstein et al., 1992; Li et al., 1993) indicated ylated by EGF treatment. By demonstrating that the ICP10
PK catalytic domain can function as an inducible kinase,that p210CH5 binds proteins p88, p60, p44, and p34, the
identities of which are still unknown, as well as proteins our findings support previous conclusions that the ICP10
auto- and transphosphorylating activities are intrinsicp170 and p25, which are consistent with the hsos–Grb2
complex (Chardin et al., 1993; Li et al., 1993) and were (Smith et al., 1994; Chung et al., 1989; Luo and Aurelian,
1992). The alternative interpretation is that PK activity isidentified as such by immunoblotting of the precipitates
with the respective antibodies (C. C. Smith et al., in prepa- mediated by a cellular kinase which is intimately associ-
ated with ICP10 but, miraculously, it remains invisibleration), and a p120 species that is recognized by anti-
ras-GAP antibody. This is consistent with previous find- under all the experimental conditions studied so far and
does not contribute to the specific properties [viz. cationings that hsos-Grb2 and ras-GAP bind to ICP10 in the
stably transfected transformed human cells JHLa1 (Smith requirements (Peng et al., 1996)] of the ICP10 kinase
activity. This interpretation implies that EGF activates theet al., 1994). ras-GAP binding to p210CH5 was indepen-
dent of EGF stimulation, suggesting that it is similar to invisible contaminant without transmitting its signal
through p210CH5, which is its only receptor in CH5 cells.that evidenced by ICP10 (in JHLa1 cells), but differs from
that evidenced by EGFR which complexes with signaling In addition to contradicting all available data on ligand-
induced signaling, this fanciful interpretation is illogicalproteins only after it is ligand-activated (Lowenstein et
al., 1992; van der Geer et al., 1994). Presumably, ligand- and cannot be taken seriously.
Further studies are required to determine whether thetriggered activation is required for EGFR binding of sig-
naling proteins in order to phosphorylate the Tyr residues EGF-initiated signal in CH5 cells is routed through the
same pathway as that described for ICP10 (Smith et al.,recognized by SH2 modules on these proteins (van der
Geer et al., 1994). Binding by ICP10 and the EGFR/ICP10 1994; Hunter et al., 1995a) to cause increased cell prolif-
eration. Ongoing studies are designed to address thishybrid, on the other hand, is likely to involve SH3 modules
the ligands of which are unphosphorylated proline-rich question and identify the other proteins that bind p21CH5
and are phosphorylated by EGF treatment. The effectregions (Pawson, 1995).
Significantly, p210CH5 evidenced ligand-inducible ki- of ligand stimulation on activation of the ras signaling
pathway, DNA synthesis, and anchorage-independentnase activity. Thus, p210CH5 was phosphorylated in EGF-
treated, but not untreated cells, and EGF treatment in- growth and the role of the ICP10 proline-rich sequences
in ras-GAP binding are also under investigation.duced the phosphorylation of the coprecipitating p120
(ras-GAP) protein. Phosphoamino acid analysis of
p210CH5 and the coprecipitated ras-GAP indicated that ACKNOWLEDGMENTS
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